{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:15:17Z","timestamp":1786119317131,"version":"build-2736575974"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1097\/cad.0b013e32831f8ec9","type":"journal-article","created":{"date-parts":[[2009,2,11]],"date-time":"2009-02-11T03:17:46Z","timestamp":1234322266000},"page":"165-173","source":"Crossref","is-referenced-by-count":11,"title":["Weekly high-dose 5-fluorouracil as a 24-h infusion and sodium folinic acid (AIO regimen) plus irinotecan in patients with locally advanced nonresectable and metastatic adenocarcinoma or squamous cell carcinoma of the oesophagus: a phase II trial"],"prefix":"10.1097","volume":"20","author":[{"given":"Kerstin","family":"Wolff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Wein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udo","family":"Reulbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gudrun","family":"M\u00e4nnlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeska","family":"Br\u00fcckl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Meier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Ostermeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siegfried A.","family":"Schwab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Horbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Hohenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eckhart G.","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Boxberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20210203","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/(SICI)1097-0215(19990924)83:1<18::AID-IJC5>3.0.CO;2-M","article-title":"Estimates of the worldwide mortality from 25 cancers in 1990","volume":"83","author":"Pisani","year":"1999","journal-title":"Int J Cancer"},{"key":"R2-2-20210203","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S0959-8049(01)00267-2","article-title":"Cancer burden in the year 2000. The global picture","volume":"37","author":"Parkin","year":"2001","journal-title":"Eur J Cancer"},{"key":"R3-2-20210203","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3322\/canjclin.57.1.43","article-title":"Cancer Statistics, 2007","volume":"57","author":"Jemal","year":"2007","journal-title":"CA Cancer J Clin"},{"key":"R4-2-20210203","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/1097-0142(20010801)92:3<549::AID-CNCR1354>3.0.CO;2-L","article-title":"Demographic variations in the rising incidence of esophageal adenocarcinoma in white males","volume":"92","author":"Bollschweiler","year":"2001","journal-title":"Cancer"},{"key":"R5-2-20210203","first-page":"631","article-title":"Changes and complication rate in surgery for thoracic esophageal carcinoma","volume":"128","author":"Meyer","year":"2003","journal-title":"Zentralbl Chir"},{"key":"R6-2-20210203","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S0305-7372(03)00104-X","article-title":"Oesophageal cancer: new developments in systemic therapy","volume":"29","author":"Ilson","year":"2003","journal-title":"Cancer Treat Rev"},{"key":"R7-2-20210203","first-page":"3709","article-title":"Kompendium Internistische Onkologie, Standards in Diagnostik und Therapie, Teil 2. 4th ed","author":"Stahl","year":"2006"},{"key":"R8-2-20210203","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.ejca.2007.03.024","article-title":"Oesophageal cancer in The Netherlands: increasing incidence and mortality but improving survival","volume":"43","author":"Crane","year":"2007","journal-title":"Eur J Cancer"},{"key":"R9-2-20210203","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJM199903183401101","article-title":"Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma","volume":"390","author":"Lagergren","year":"1999","journal-title":"N Engl J Med"},{"key":"R10-2-20210203","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1001\/jama.287.15.1972","article-title":"Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: scientific review","volume":"287","author":"Shaheen","year":"2002","journal-title":"JAMA"},{"key":"R11-2-20210203","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1093\/aje\/153.2.114","article-title":"Excess incidence of squamous cell esophageal cancer among US Black men: role of social class and other risk factors","volume":"153","author":"Brown","year":"2001","journal-title":"Am J Epidemiol"},{"key":"R12-2-20210203","first-page":"1","article-title":"Gastroenterologische Onkologie. 2nd ed","author":"Sahm","year":"2003"},{"key":"R13-2-20210203","article-title":"EUCAN: cancer in the European Union, 1995, version 2.0. IARC Cancer Base No. 4","author":"Ferlay","year":"1999"},{"key":"R14-2-20210203","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1056\/NEJMra035010","article-title":"Esophageal cancer","volume":"349","author":"Enzinger","year":"2003","journal-title":"N Engl J Med"},{"key":"R15-2-20210203","article-title":"TNM Classification of Malignant Tumours","year":"2002"},{"key":"R16-2-20210203","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/00000658-200109000-00010","article-title":"Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1000 consecutive resections at a single center in the Western world","volume":"234","author":"Siewert","year":"2001","journal-title":"Ann Surg"},{"key":"R17-2-20210203","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/00000658-200107000-00005","article-title":"Skeletonizing en bloc esophagectomy for cancer","volume":"234","author":"Collard","year":"2001","journal-title":"Ann Surg"},{"key":"R18-2-20210203","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1634\/theoncologist.4-2-95","article-title":"Surgical management for esophageal carcinoma","volume":"4","author":"Reed","year":"1999","journal-title":"Oncologist"},{"key":"R20-2-20210203","first-page":"19","article-title":"Gastrointestinale Tumoren, Empfehlungen zur Diagnostik, Therapie und Nachsorge, Teil 1. 7th ed","author":"Stein","year":"2006"},{"key":"R21-2-20210203","first-page":"2705","article-title":"Palliative chemotherapy for recurrent and metastatic esophageal cancer","volume":"27","author":"Gr\u00fcnberger","year":"2007","journal-title":"Anticancer Res"},{"issue":"15","key":"R22-2-20210203","first-page":"12","article-title":"Chemotherapy in esophageal cancer","volume":"26","author":"Enzinger","year":"1999","journal-title":"Semin Oncol"},{"key":"R23-2-20210203","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/S0959-8049(97)00088-9","article-title":"Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cispaltin alone in advanced squamous cell oesophageal cancer","volume":"33","author":"Bleiberg","year":"1997","journal-title":"Eur J Cancer"},{"key":"R24-2-20210203","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/sj.bjc.6600166","article-title":"Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer","volume":"86","author":"Polee","year":"2002","journal-title":"Br J Cancer"},{"key":"R25-2-20210203","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1200\/JCO.2002.08.105","article-title":"Prospective randomized trial comparing mitomycin, cisplatin, and protacted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin and PVI 5-FU in advanced esophagogastric cancer","volume":"20","author":"Ross","year":"2002","journal-title":"J Clin Oncol"},{"key":"R26-2-20210203","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/00001813-200107000-00004","article-title":"Phase II study of the combination cisplatin, etoposide, 5-fluorouracil and folinic acid in patients with advanced squamous cell carcinoma of the oesophagus","volume":"12","author":"Polee","year":"2001","journal-title":"Anti-Cancer Drugs"},{"key":"R27-2-20210203","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1038\/sj.bjc.6602572","article-title":"Report of two protocol planned interim analyses in a randomised multicenter phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF","volume":"92","author":"Sumpter","year":"2005","journal-title":"Br J Cancer"},{"key":"R28-2-20210203","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1038\/sj.bjc.6603750","article-title":"First line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer. A phase II study","volume":"96","author":"Meerten van","year":"2007","journal-title":"Br J Cancer"},{"key":"R29-2-20210203","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1200\/JCO.1999.17.10.3270","article-title":"Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer","volume":"17","author":"Ilson","year":"1999","journal-title":"J Clin Oncol"},{"issue":"8","key":"R30-2-20210203","first-page":"27","article-title":"Phase II study of docetaxel and irinotecan in metastatic or recurrent esophageal cancer: a preliminary report","volume":"17","author":"Govindan","year":"2003","journal-title":"Oncology"},{"key":"R31-2-20210203","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/sj.bjc.6601168","article-title":"Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer","volume":"89","author":"Lordick","year":"2003","journal-title":"Br J Cancer"},{"key":"R32-2-20210203","doi-asserted-by":"crossref","first-page":"4856","DOI":"10.1200\/JCO.2005.05.546","article-title":"Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986","volume":"23","author":"K\u00f6hne","year":"2005","journal-title":"J Clin Oncol"},{"key":"R33-2-20210203","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1038\/sj.bjc.6602649","article-title":"Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leukovorin and etoposide (ELF) in untreated metastatic gastric cancer","volume":"92","author":"Moehler","year":"2005","journal-title":"Br J Cancer"},{"key":"R34-2-20210203","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1200\/JCO.2004.01.140","article-title":"Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leukovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a F\u00e9d\u00e9ration Francophone de Canc\u00e9rologie Digestive Group Study-FFCD 9803","volume":"22","author":"Bouch\u00e9","year":"2004","journal-title":"J Clin Oncol"},{"key":"R35-2-20210203","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/028418699431690","article-title":"Outpatient 5-fluorouracil, folinic acid and cisplatin in patients with advanced esophageal carcinoma","volume":"38","author":"Warner","year":"1999","journal-title":"Acta Oncol"},{"key":"R36-2-20210203","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1016\/S0959-8049(01)00180-0","article-title":"A weekly 24-h infusion of high-dose 5 fluorouracil (5-FU) +leucovorin and bi-weekly cisplatin (CDDP) was active and well tolerated in patients with non-colon digestive carcinomas","volume":"37","author":"Caroli-Bosc","year":"2001","journal-title":"Eur J Cancer"},{"key":"R37-2-20210203","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/jjco\/hye090","article-title":"Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG) Trial (JCOG9407)","volume":"31","author":"Hayashi","year":"2001","journal-title":"Jpn J Clin Oncol"},{"key":"R38-2-20210203","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/BF02482231","article-title":"Phase II trial of 5-fluorouracil and low-dose cisplatin in patients with squamous cell carcinoma of the esophagus","volume":"29","author":"Sekiguchi","year":"1999","journal-title":"Surg Today"},{"key":"R39-2-20210203","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s00384-002-0464-x","article-title":"A pilot study of irinotecan (CPT-11) as single-agent therapy in patients with locally advanced or metastatic esophageal carcinoma","volume":"18","author":"M\u00fchr-Wilkenshoff","year":"2003","journal-title":"Int J Colorectal Dis"},{"issue":"14","key":"R40-2-20210203","first-page":"22","article-title":"Phase II trial of weekly irinotecan\/cisplatin in advanced esophageal cancer","volume":"18","author":"Ilson","year":"2004","journal-title":"Oncology"},{"key":"R41-2-20210203","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/annonc\/mdn166","article-title":"Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction","volume":"19","author":"Dank","year":"2008","journal-title":"Ann Oncol"},{"key":"R42-2-20210203","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1093\/annonc\/mdl459","article-title":"Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastrooesophageal junction adenocarcinoma (FOLCETUX study)","volume":"18","author":"Pinto","year":"2007","journal-title":"Ann Oncol"}],"container-title":["Anti-Cancer Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CAD.0b013e32831f8ec9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:57:45Z","timestamp":1786039065000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001813-200903000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/cad.0b013e32831f8ec9","relation":{},"ISSN":["0959-4973"],"issn-type":[{"value":"0959-4973","type":"print"}],"subject":[],"published":{"date-parts":[[2009,3]]}}}